SSR240600C Treatment in Women With Overactive Bladder

• Status: Completed
• Trial end date: 2009-02-01
• Target enrollment: 0
• Participant gender: Female

Summary

The primary objective of this study is to evaluate the efficacy of SSR240600C in women with overactive bladder compared to placebo using tolterodine as a study calibrator.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sanofi
• Treatments: Tolterodine Tartrate

Criteria

Inclusion Criteria:

• Diagnosis of overactive bladder

Exclusion Criteria:

• Stress incontinence or mixed incontinence where stress incontinence is the predominant component based on prior history

• Urinary incontinence due to cause other than detrusor overactivity (eg, overflow incontinence)

• Current Urinary Tract Infection (UTI) or frequent UTIs

• Urinary retention or other evidence of poor detrusor function

• Pain during voiding or bladder pain without voiding

• History of radiation cystitis or history of pelvic irradiation

• History of interstitial cystitis or bladder related pain syndrome

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.